Previous Close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.1000 |
Strike | 2.50 |
Expire Date | 2024-05-17 |
Day's Range | 0.1000 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 558 |
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2024. Details of the conferences appear below: Conference: RBC Capital Markets Glob
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...